GENB (Generate Biomedicines) ROC (Joel Greenblatt) %: -233.24% (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines ROC (Joel Greenblatt) %?

Generate Biomedicines GENB +2.18% 6 ROC (Joel Greenblatt) % is -233.24% as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,325 Biotechnology companies, Generate Biomedicines ranks better than 52.68% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Generate Biomedicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -233.24%.

The historical rank and industry rank for Generate Biomedicines's ROC (Joel Greenblatt) % or its related term are showing as below:

GENB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -233.24   Med: -205.2   Max: -177.16
Current: -233.24

During the past 2 years, Generate Biomedicines's highest ROC (Joel Greenblatt) % was -177.16%. The lowest was -233.24%. And the median was -205.20%.

GENB's ROC (Joel Greenblatt) % is ranked better than
52.68% of 1325 companies
in the Biotechnology industry
Industry Median: -297.52 vs GENB: -233.24

Generate Biomedicines's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Generate Biomedicines  (NAS:GENB) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Generate Biomedicines ROC (Joel Greenblatt) % Related Terms


Generate Biomedicines ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines ROC (Joel Greenblatt) % Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
ROC (Joel Greenblatt) %
-177.16 -233.24

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
ROC (Joel Greenblatt) % -177.16 -233.24

GENB vs PVLA, SLBT, NKTR: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Generate Biomedicines's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generate Biomedicines ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's ROC (Joel Greenblatt) % falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.308 + 0 + 13.556) - (11.701 + 42.425 + 15.783)
=-56.045

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 12.867) - (29.575 + 21.194 + 16.426)
=-54.328

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Generate Biomedicines for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-221.666/( ( (101.068 + max(-56.045, 0)) + (89.011 + max(-54.328, 0)) )/ 2 )
=-221.666/( ( 101.068 + 89.011 )/ 2 )
=-221.666/95.0395
=-233.24 %

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -233.24% mean?
Generate Biomedicines (GENB) has a ROC (Joel Greenblatt) % of -233.24% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #627 out of 1325 companies in the Biotechnology industry, placing it in the top 47.3%.
Is Generate Biomedicines' ROC (Joel Greenblatt) % too high?
Generate Biomedicines' current ROC (Joel Greenblatt) % is -233.24%. Based on the distribution chart, Generate Biomedicines ranks #627 out of 1325 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' ROC (Joel Greenblatt) % compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #627 out of 1325 companies for ROC (Joel Greenblatt) %. This puts Generate Biomedicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current ROC (Joel Greenblatt) % is -233.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current ROC (Joel Greenblatt) % of -233.24%. The current ROC (Joel Greenblatt) % is -233.24%. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current ROC (Joel Greenblatt) % is -233.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price